The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Plasma-derived Hyperimmune Product Market Research Report 2024
Synopsis
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Human Plasma-derived Hyperimmune Product market is projected to reach US$ 2839.8 million in 2029, increasing from US$ 1867 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Plasma-derived Hyperimmune Product market research.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Human Plasma-derived Hyperimmune Product market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institution
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Plasma-derived Hyperimmune Product report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Human Plasma-derived Hyperimmune Product market is projected to reach US$ 2839.8 million in 2029, increasing from US$ 1867 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Plasma-derived Hyperimmune Product market research.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Human Plasma-derived Hyperimmune Product market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institution
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Plasma-derived Hyperimmune Product report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Human Plasma-derived Hyperimmune Product Market Overview
1.1 Product Overview and Scope of Human Plasma-derived Hyperimmune Product
1.2 Human Plasma-derived Hyperimmune Product Segment by Type
1.2.1 Global Human Plasma-derived Hyperimmune Product Market Value Comparison by Type (2023-2029)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Human Plasma-derived Hyperimmune Product Segment by Application
1.3.1 Global Human Plasma-derived Hyperimmune Product Market Value by Application: (2023-2029)
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Others
1.4 Global Human Plasma-derived Hyperimmune Product Market Size Estimates and Forecasts
1.4.1 Global Human Plasma-derived Hyperimmune Product Revenue 2018-2029
1.4.2 Global Human Plasma-derived Hyperimmune Product Sales 2018-2029
1.4.3 Global Human Plasma-derived Hyperimmune Product Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Human Plasma-derived Hyperimmune Product Market Competition by Manufacturers
2.1 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Manufacturers (2018-2023)
2.2 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Human Plasma-derived Hyperimmune Product Average Price by Manufacturers (2018-2023)
2.4 Global Human Plasma-derived Hyperimmune Product Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Product Type & Application
2.7 Human Plasma-derived Hyperimmune Product Market Competitive Situation and Trends
2.7.1 Human Plasma-derived Hyperimmune Product Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Plasma-derived Hyperimmune Product Players Market Share by Revenue
2.7.3 Global Human Plasma-derived Hyperimmune Product Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Plasma-derived Hyperimmune Product Retrospective Market Scenario by Region
3.1 Global Human Plasma-derived Hyperimmune Product Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Human Plasma-derived Hyperimmune Product Global Human Plasma-derived Hyperimmune Product Sales by Region: 2018-2029
3.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2018-2023
3.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2024-2029
3.3 Global Human Plasma-derived Hyperimmune Product Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2018-2029
3.3.1 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2018-2023
3.3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2024-2029
3.4 North America Human Plasma-derived Hyperimmune Product Market Facts & Figures by Country
3.4.1 North America Human Plasma-derived Hyperimmune Product Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Human Plasma-derived Hyperimmune Product Sales by Country (2018-2029)
3.4.3 North America Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Plasma-derived Hyperimmune Product Market Facts & Figures by Country
3.5.1 Europe Human Plasma-derived Hyperimmune Product Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2018-2029)
3.5.3 Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Plasma-derived Hyperimmune Product Market Facts & Figures by Country
3.6.1 Asia Pacific Human Plasma-derived Hyperimmune Product Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Country (2018-2029)
3.6.3 Asia Pacific Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Plasma-derived Hyperimmune Product Market Facts & Figures by Country
3.7.1 Latin America Human Plasma-derived Hyperimmune Product Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Human Plasma-derived Hyperimmune Product Sales by Country (2018-2029)
3.7.3 Latin America Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Plasma-derived Hyperimmune Product Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Plasma-derived Hyperimmune Product Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2018-2029)
3.8.3 Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2018-2029)
4.1.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023)
4.1.2 Global Human Plasma-derived Hyperimmune Product Sales by Type (2024-2029)
4.1.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2029)
4.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2018-2029)
4.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2018-2023)
4.2.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2024-2029)
4.2.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2018-2029)
4.3 Global Human Plasma-derived Hyperimmune Product Price by Type (2018-2029)
5 Segment by Application
5.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2018-2029)
5.1.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023)
5.1.2 Global Human Plasma-derived Hyperimmune Product Sales by Application (2024-2029)
5.1.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2029)
5.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2018-2029)
5.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2018-2023)
5.2.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2024-2029)
5.2.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2018-2029)
5.3 Global Human Plasma-derived Hyperimmune Product Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Grifols Human Plasma-derived Hyperimmune Product Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biotest Human Plasma-derived Hyperimmune Product Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CBPO Human Plasma-derived Hyperimmune Product Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kamada Human Plasma-derived Hyperimmune Product Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CNBG Human Plasma-derived Hyperimmune Product Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Human Plasma-derived Hyperimmune Product Description and Business Overview
6.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2018-2023)
6.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Plasma-derived Hyperimmune Product Industry Chain Analysis
7.2 Human Plasma-derived Hyperimmune Product Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Plasma-derived Hyperimmune Product Production Mode & Process
7.4 Human Plasma-derived Hyperimmune Product Sales and Marketing
7.4.1 Human Plasma-derived Hyperimmune Product Sales Channels
7.4.2 Human Plasma-derived Hyperimmune Product Distributors
7.5 Human Plasma-derived Hyperimmune Product Customers
8 Human Plasma-derived Hyperimmune Product Market Dynamics
8.1 Human Plasma-derived Hyperimmune Product Industry Trends
8.2 Human Plasma-derived Hyperimmune Product Market Drivers
8.3 Human Plasma-derived Hyperimmune Product Market Challenges
8.4 Human Plasma-derived Hyperimmune Product Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
